What is the recommended treatment for Crohn's disease–related skin lesions such as erythema nodosum and pyoderma gangrenosum?

Treatment of Crohn's Disease-Related Skin Lesions

For Crohn's disease-related skin lesions, treatment should primarily target the underlying intestinal disease activity, with erythema nodosum responding to systemic corticosteroids and immunomodulators, while pyoderma gangrenosum requires aggressive immunosuppression with infliximab or adalimumab as first-line therapy for rapid healing.

Erythema Nodosum (EN)

Treatment Approach

• Primary strategy: Treat the underlying IBD activity, as EN typically parallels intestinal disease flares 1
• Systemic corticosteroids are required for severe cases that don't respond to IBD-directed therapy alone 1
• For relapsing or resistant forms, escalate to immunomodulators (azathioprine) or anti-TNF agents (infliximab or adalimumab) 1

Clinical Context

• EN affects 4.2-7.5% of IBD patients, more commonly in Crohn's disease than ulcerative colitis 1
• Lesions present as raised, tender, red or violet subcutaneous nodules (1-5cm diameter) on the anterior tibial areas 1
• Diagnosis is clinical; biopsy only needed in atypical cases 1
• Infliximab has demonstrated high effectiveness for refractory EN lesions 2, 3

Pyoderma Gangrenosum (PG)

Treatment Algorithm

First-line therapy:

• Infliximab should be considered early if rapid response to corticosteroids cannot be achieved 1
• The landmark randomized controlled trial showed 46% improvement with infliximab at Week 2 versus 6% with placebo (p=0.025), with overall response rate of 69% and remission rate of 31% 1
• Response rates exceed 90% when PG duration is <12 weeks, but drop below 50% for chronic lesions 1

Alternative first-line options:

• Systemic corticosteroids (traditional first-line) 1
• Topical or oral calcineurin inhibitors (pimecrolimus or tacrolimus) with dermatology consultation 1

Second-line therapy:

• Adalimumab has demonstrated efficacy in case series 1
• Oral ciclosporin or intravenous tacrolimus for refractory cases 1
• Ustekinumab may be effective when anti-TNF therapy fails 4

Clinical Pearls

• The therapeutic goal must be rapid healing, as PG is debilitating and can expose deep tissues 1
• PG occurs in 0.6-2.1% of IBD patients, affecting shins and peristomal areas most commonly 1
• Lesions begin as pustules that rapidly become burrowing ulcers with violaceous edges 1
• Avoid trauma (pathergy phenomenon) - lesions often preceded by injury 1
• PG recurs in >25% of cases, often at the same site 1
• For peristomal PG, stoma closure may lead to resolution 1
• Daily wound care with a wound-care specialist is essential 1

Important Caveats

Paradoxical Anti-TNF-Induced Skin Lesions

• Anti-TNF therapy itself can paradoxically induce cutaneous lesions (psoriasiform, eczematous, or lupus-like) 5
• Management requires multidisciplinary assessment with dermatology 5
• Mild psoriasiform or eczematous lesions: Topical management 5
• Moderate/severe psoriasiform lesions: Switch to another anti-TNF or change biologic class 5
• Lupus-like lesions: Discontinue anti-TNF therapy 5

Monitoring Considerations

• The 2025 British Society of Gastroenterology guidelines emphasize drug monitoring for all immunosuppressants used in IBD 5
• Vedolizumab and ustekinumab show lower serious infection risk compared to anti-TNF agents, though this was primarily demonstrated in ulcerative colitis 5

Diagnostic Considerations

• PG is a diagnosis of exclusion - must rule out infection, vasculitis, and arterial/venous insufficiency 1
• Biopsy from lesion periphery can help exclude other disorders but findings are non-specific 1
• EN diagnosis is clinical; metastatic Crohn's disease (with non-caseating granulomas) is the key differential 1